Two analyses of updated three-year follow-up data from the pivotal Phase 2 FIREFLY-1 study of OJEMDA® (tovorafenib) in BRAF-altered pediatric low-grade glioma will be featured in separate oral presentationsResults from a survey of pediatric low-grade glioma caregivers unveiling…
News provided by PR Newswire.
